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Regulation of metabolic pathways plays an impor-
tant role in controlling cell growth, proliferation, and
survival. TIGAR acts as a fructose-2,6-bisphospha-
tase, potentially promoting the pentose phosphate
pathway to produce NADPH for antioxidant function
and ribose-5-phosphate for nucleotide synthesis.
The functions of TIGAR were dispensable for normal
growth and development in mice but played a key
role in allowing intestinal regeneration in vivo and in
ex vivo cultures, where growth defects due to lack
of TIGAR were rescued by ROS scavengers and nu-
cleosides. In a mouse intestinal adenoma model,
TIGAR deficiency decreased tumor burden and
increased survival, while elevated expression of
TIGAR in human colon tumors suggested that de-
regulated TIGAR supports cancer progression. Our
study demonstrates the importance of TIGAR in
regulating metabolism for regeneration and cancer
development and identifies TIGAR as a potential
therapeutic target in diseases such as ulcerative co-
litis and intestinal cancer.
INTRODUCTION
The ability to regulate metabolic pathways is key to maintaining
normal health and homeostasis, and defects in these responses
contribute to major diseases such as diabetes and cancer. Mod-
ulation of metabolic pathways plays an important role in tumor-
igenesis, where metabolic transformation underpins the
abnormal growth, proliferation, and survival of cancer cells.
The expression of the M2 isoform of pyruvate kinase, for
example, allows the diversion of glycolytic intermediates into
various anabolic pathways (including the pentose phosphate
pathway [PPP]) to support cancer cell growth (Anastasiou
et al., 2011; Ye et al., 2012). The use of glutamine for anaplerosis
(Wise and Thompson, 2010) and the expression of mutant forms
of isocitrate dehydrogenase (Borodovsky et al., 2012) are further
examples where altered metabolism plays a role in promoting
oncogenic transformation. Components of many metabolic
pathways are modified by both tumor suppressors and onco-
genes, and drugs that targetmetabolic enzymes are being devel-
oped as cancer therapies (Cairns et al., 2011; Dang, 2012). How-Develever, the contribution of these enzymes to tumor development
and the balance between their roles in allowing normal cell
growth and supporting cancer progression are not well explored
in vivo, possibly due to the fact that modulation of many of these
enzymes is deleterious to embryonic development (Piruat et al.,
2004; Pollard et al., 2007; Yang et al., 2010b).
TIGAR functions as a fructose-2,6-bisphosphatase (Fru-2,6-
BPase), decreasing the intracellular levels of fructose-2,6-
bisphosphate (Fru-2,6-BP) and thereby lowering the activity of
PFK1 and flux through the main glycolytic pathway. As a conse-
quence, glucose metabolism may be diverted into the PPP, and
TIGAR has been shown to support increased production of
NADPH and antioxidant activity through the generation of
reduced glutathione (Bensaad et al., 2006; Bensaad and Vous-
den, 2007; Li and Jogl, 2009;Wanka et al., 2012). Several studies
have shown the importance of TIGAR in controlling reactive ox-
ygen species (ROS) in tissue culture systems (Bensaad et al.,
2006, 2009; Yin et al., 2012) and elevated expression of TIGAR
has been reported in some cancer models (Wanka et al., 2012;
Won et al., 2012).
The potential importance of TIGAR in tumor development is
illustrated by a study showing that the depletion of PFKFB4 (an
enzyme with fructose-2,6-bisphosphatase activity like TIGAR)
and the subsequent decrease in ROS scavengers can inhibit tu-
mor growth in a xenograph model (Ros et al., 2012). An RNA
interference screen in glioma stem-like cells also identified
PFKFB4 as an essential gene for tumor survival (Goidts et al.,
2012). Furthermore, additional consequences of promotion of
the PPP, including the support of other anabolic reactions that
require NADPH, such as fatty acid synthesis, and the generation
of ribose phosphate for DNA synthesis and repair (Deberardinis
et al., 2008; Kroemer and Pouyssegur, 2008; Tong et al., 2009;
Vander Heiden et al., 2009) may play a role in tumor develop-
ment. Taken together, it is possible that expression of TIGAR
and subsequent changes in metabolic pathway utilization could
help to promote tumor development. However, the overall
contribution of TIGAR to normal growth and development has
not been determined.
TIGAR was initially identified as a transcriptional target of p53
(Bensaad et al., 2006). p53 is a critical tumor suppressor protein
that functions to prevent the growth or survival of cells that are
undergoing malignant progression by inducing apoptosis or
senescence in response to oncogenic stress. However, more
recent studies have shown that p53 can also function to control
metabolism (Vousden and Ryan, 2009), and TIGAR contributes
to this activity of p53. The activation of TIGAR and other genes
by p53 promotes an antioxidant response (Bensaad et al.,opmental Cell 25, 463–477, June 10, 2013 ª2013 Elsevier Inc. 463
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cells to survive transient or low levels of stress, and has recently
also been suggested to play a key role in preventing malignant
progression (Li et al., 2012). However, TIGAR overexpression
has also been described in a few tumor types (Wanka et al.,
2012; Won et al., 2012), raising the possibility that deregulated
expression of TIGAR may play a role in supporting, rather than
inhibiting, cancer development.
In order to determine the role of TIGAR in normal development
and its contribution to proliferation under conditions of tissue
repair or malignant growth, we generated TIGAR-deficient
mice. While TIGAR does not appear to be essential for normal
development, animals lacking TIGAR show a clear defect in their
ability to mount a proliferative response in adult tissue, either in
response to tissue damage or tumor development. TIGAR levels
are elevated in mouse and human tumors and tumor cell lines,
regardless of the presence or absence of wild-type (WT) p53,
and a reduction of TIGAR increased survival in a mouse model
of intestinal adenoma. Taken together, our data show that TIGAR
contributes to both tissue regeneration and tumor development.
RESULTS
Generation of TIGAR-Deficient Mice
Two independent approaches were taken to generate TIGAR-
deficient mice. A constitutive deletion was generated using a
genetrap construct from EUCOMM, in which the targeting vector
was inserted between exons 2 and 3 of the TIGAR gene (Fig-
ure S1A available online). Lack of TIGAR protein expression
was confirmed by western blotting lysates from various tissues
derived from these mice (Figure 1A). Deletion of TIGAR did not
lead to obvious developmental problems, and TIGAR/ mice
were born at the expectedMendelian ratio (Figure 1B). In parallel,
we also generated a conditional TIGARfl/fl mouse by targeting
exon 3, the deletion of which resulted in a frame shift and com-
plete loss of expression of TIGAR protein in the presence of
the germline deleter cre (Figures S1B and S1C).
Muchof the analysis of TIGAR function todatehasbeencarried
out in humancells (Bensaad et al., 2006; Li and Jogl, 2009), and to
confirmasimilar functionofmouseTIGAR,we testedbabymouse
kidney (BMK) cells derived from TIGAR/ mice for Fru-2,6-BP
levels and reduced glutathione (GSH)/oxidized glutathione
(GSSG) ratios (Figures 1C–1E). Cells lacking TIGAR showed
increased Fru-2,6-BP levels and lower GSH/GSSG ratios. These
results are therefore consistent with the described role of human
TIGAR as a Fru-2,6-BPase that increases NADPH and subse-
quently lowers the GSH/GSSG ratio (Bensaad et al., 2006; Li
and Jogl, 2009). As expected, TIGAR-deficient cells were more
sensitive to oxidative stress following treatment with H2O2 (Fig-
ure 1F). Reintroduction of human TIGAR into these cells to levels
comparablewith those seen inWTcells (Figure 1C) rescued these
phenotypes (Figures 1D and 1F), confirming that the effects seen
weredue to the lackofTIGAR in thesecells and thatmouseTIGAR
functions similarly to human TIGAR.
TIGAR Is Required for Small Intestine Proliferation after
Acute Damage
While lack of TIGAR in developing embryos or unstressed adults
did not result in a clear change in phenotype, we considered that464 Developmental Cell 25, 463–477, June 10, 2013 ª2013 Elsevier ITIGAR expression may play a more important role under condi-
tions of stress in adult tissue. To address this question, we
focused on the intestine as an organ in which cell proliferation
plays an important role during regeneration following tissue abla-
tion. Analysis of small intestine (Figure 1G) or colon (Figure 1H)
from untreated mice showed normal intestinal crypt architecture
and proliferation in TIGAR-deficient mice compared to WT ani-
mals. TIGAR protein expression in WT animals was localized
mainly in the intestinal crypt (Figures 1G and 1H), where most
of the proliferation occurs. Importantly, no staining was seen in
the intestines or colon of TIGAR-null mice.
To examine the role of TIGAR in proliferation and regeneration
of adult intestinal epithelium, we turned to well-definedmodels in
which ablation of intestinal epithelium by irradiation (IR) or treat-
ment with a genotoxic drug is followed by a period of recovery
and rapid tissue regeneration. InWTmice, small intestinal regen-
eration is characterized by a rapid regrowth of intestinal crypts,
which can be seen 72 hr following treatment with 14 Gy IR (Fig-
ures 2A and 2B). By comparison, TIGAR-deficient mice showed
a significant reduction in both the size and number of regenerat-
ing crypts (Figures 2A and 2B). To determine the underlying
cause of this defect, we examined both proliferation and cell
death in the small intestine of mice after IR. Using the prolifera-
tion marker Ki67, it was clear that while both WT and TIGAR/
mice showed an initial decrease in proliferation 24 hr post-IR,
only the WT animals moved to a phase of rapid proliferation
that was evident 48 and 72 hr post-IR and was consistent with
the outgrowth of new crypt structures (Figures 2C and 2D). The
TIGAR/ mice showed a clear defect in proliferation at these
time points (Figures 2C and 2D). Measurements of cell death in
the intestine indicated an increase in the number of dying cells
in the TIGAR/ compared to WT intestines 6 hr post-IR (Figures
2E and 2F), although by 24 or 48 hr minimal cell death was de-
tected in mice of either genotype. Analysis of progenitor cells us-
ing immunohistochemistry of markers such as LGR5 or Olfm4
(van der Flier et al., 2009) revealed a similar staining pattern be-
tween TIGAR/ and WT animals (Figure S2A). The staining in-
tensity was somewhat reduced in TIGAR-deficient animals after
acute injury (Figure S2A), although the interpretation of this effect
is limited by the difficulty in finding intact crypts to stain after
damage. Taken together with the data showing only a transient
increase in apoptosis in TIGAR-null intestines 6 hr after damage
(Figures 2E and 2F), these results suggest that the defects in pro-
liferation in the absence of TIGAR are not simply the result of
massive apoptosis during the period of maximal regeneration
(24–48 hr) or complete depletion of the stem cell population at
an earlier time point, but also reflect a failure to proliferate.
Consistent with the role of TIGAR in supporting intestinal pro-
liferation after damage, TIGAR immunostaining in WT tissues re-
vealed a marked and sustained increase in TIGAR expression in
intestinal crypts 24 and 72 hr after IR (Figure 2G). Previous
studies have demonstrated a role of TIGAR in lowering ROS
(Bensaad et al., 2006; Li and Jogl, 2009; Wanka et al., 2012),
and we have shown that TIGAR-deficient BMK cells have less
GSHandaremore sensitive toH2O2 (Figures 1E and 1F). Analysis
of intestinal tissue formarkers of ROS accumulation also showed
an increase in MDA (malondialdehyde, an indicator for lipid per-
oxidation) staining after IR inTIGAR/mice compared toWTan-
imals (Figure 2H), indicating that TIGAR is also important to limitnc.
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Figure 1. TIGAR-Deficient Mice
(A) Western blot analysis of the indicated tissues from WT and TIGAR-deficient animals.
(B) Mendelian ratio from TIGAR+/ matings.
(C) Western blot analysis of baby mouse kidney (BMK) cultures from wild-type (WT), TIGAR/ (KO), and KO cultures transfected with human TIGAR construct.
(D) Level of fructose-2,6-bisphosphate in WT, KO, and KO BMK cell cultures transfected with TIGAR construct (KO + TIGAR). *p < 0.05 compared to WT; **p <
0.05 compared to KO.
(E) Ratio of oxidized and reduced glutathione (GSH/GSSG) of WT, KO, and KO + TIGAR BMK cells. *p < 0.05 compared to WT; **p < 0.05 compared to KO.
(F) Cell death as measured by PI exclusion of WT, KO, and KO + TIGAR BMK cells after hydrogen peroxide treatment. *p < 0.05 compared to WT; **p < 0.05
compared to KO.
(G and H) Untreated small intestine (G) and colon (H) fromWT and KO animals. Top: hematoxylin and eosin staining (H&E); middle: Ki67; bottom: TIGAR staining.
Scale bar, 200 mm. Data are represented as mean ± SEM (n = at least 3).
See also Figure S1.
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Figure 2. TIGAR-Deficient Mice Have Reduced Regenerative Capacity in the Intestinal Crypt after 14 Gy Whole-Body IR
(A) Small intestine from WT and TIGAR/ (KO) animals 72 hr after 14 Gy IR. Bar = 200 mm.
(B) Number of crypts per millimeter (left) and size of crypts (right) 72 hr after 14 Gy IR. *p < 0.05 compared to WT.
(C) Ki67 staining of WT and KO intestines 6 and 72 hr after 14 Gy IR. Bar = 200 mm.
(D) Quantification of Ki67+ cells at the indicated times after 14 Gy IR. *p < 0.05 compared to WT.
(E) Apoptosis in the small intestine 6 hr after 14 Gy IR. Asterisks denote cells with apoptotic nuclear morphology.
(F) Number of apoptotic cells in the crypts 6 hr after 14 Gy IR. *p < 0.05 compared to WT.
(G) TIGAR staining of WT animals before IR and 24 and 72 hr after 14 Gy IR. Scale bar, 200 mm. Panels show details of crypt structures indicated in the box.
(H)Malondialdehyde (MDA) staining ofWT andKOanimals before and 24 hr after 14Gy IR. Scale bar, 200 mm.Data are represented asmean ± SEM (n = at least 3).
See also Figure S2.
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Figure 3. TIGAR-Deficient Mice Are More Sensitive to DSS-Induced Colitis
(A) Colon from WT and TIGAR/ (KO) animals 2 days after 2% DSS treatment. Top: H&E; bottom: BrdU staining. Bar = 200 mm.
(B) Percentage of colitis area one day after 3.5% DSS in WT and KO animals. *p < 0.05 compared to WT.
(C) Percentage of colitis area one day after 2% DSS in WT and KO animals. *p < 0.05 compared to WT.
(D) Percentage of colitis area 2 days after 2% DSS in WT and KO animals. *p < 0.05 compared to WT.
(E) TIGAR staining in WT animals, untreated (ctr) or after 3.5% DSS treatment. Scale bar, 200 mm. Panels show details of crypt structures indicated in the box.
(F) MDA staining of WT and KO animals before and after 2% DSS treatment. Scale bar, 200 mm. Data are represented as mean ± SEM (n = at least 3).
See also Figure S3.
Developmental Cell
TIGAR Supports Intestinal RegenerationROS levels in vivo. The importance of TIGAR in response to IR
damage is underscored by similar effects observed following
damage induced by cisplatin (Figure S2). After cisplatin treat-
ment, TIGAR/ mice showed a reduced ability to regenerate
crypts (Figures S2B and S2C), which was accompanied by a
decrease in proliferation (Figures S2D and S2E) and an increase
in apoptosis at early time point (Figures S2F and S2G).
TIGAR Is Required for Colon Regeneration in a Model of
Ulcerative Colitis
The results described above revealed an interesting role for
TIGAR in supporting tissue growth and survival under conditions
of rapid regeneration in adult mice, consistent with the proposed
metabolic function of TIGAR. To determine whether TIGAR can
also play a role in recovery following damage in a different
setting, we investigated a model of ulcerative colitis in the colon.DevelTreatment of mice with dextran sulfate sodium (DSS) over
several days resulted in an ablation of colon epithelium, followed
by inflammation and hyperproliferation of the crypts to allow for
repair (Cooper et al., 1993). While the resting colons of WT and
TIGAR-deficient mice were indistinguishable (Figure 1H), the
extensive formation of new crypts seen in WT colons following
DSS treatment and recovery was much less apparent in
TIGAR/ animals (Figure 3A). Furthermore, compared to WT
mice, there is a defect in proliferation in TIGAR-deficient animals
after DSS treatment, as indicated by bromodeoxyuridine (BrdU)
incorporation (Figure 3A). Consistently, TIGAR/ mice sub-
jected to DSS treatment showed poorer recovery and suc-
cumbed approximately 1 day earlier thanWT animals. The differ-
ence between WT and TIGAR/ mice was more obvious
following exposure to milder damage (2% DSS) compared to a
more damaging treatment (3.5% DSS) (Figures 3B and 3C),opmental Cell 25, 463–477, June 10, 2013 ª2013 Elsevier Inc. 467
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at this time point some recovery in TIGAR/mice was also seen
(Figures 3C and 3D; note difference in scale of y axis). TIGAR
expression can therefore limit but not completely prevent dam-
age, and even in the absence of TIGAR some recovery is
possible.
Analysis of TIGAR protein levels inWTmice showed increased
expression following DSS treatment (Figure 3E), similar to that
seen in small intestine after IR damage (Figure 2G). TIGAR-defi-
cient animals accumulated elevated ROS following DSS treat-
ment, as indicated by an increase in MDA staining (Figure 3F),
suggesting an important role of TIGAR in limiting ROS damage
after DSS-induced colitis. These results indicated that, as seen
in the regenerating small intestine after IR or treatment with
cisplatin, efficient repair of damage to the colon was dependent
on TIGAR expression.
The requirement for TIGAR in intestinal regeneration was
confirmed using animals with conditional TIGAR allele (TIGARfl/fl)
crossed with deleter cre TIGARfl/fl;cre/+ animals (Figures S1B and
S1C). Loss of TIGAR expression in these animals also resulted in
increased sensitivity to DSS-induced colitis in the colon (Fig-
ure S3), recapitulating the phenotype seen with the TIGAR/
mouse. Taken together, these results show that lack of TIGAR
compromises the ability of cells to limit ROSandundergoprolifer-
ation necessary to regenerate intestinal epithelium after ablation.
TIGAR Provides Antioxidants and Nucleosides for
Growth
Our analysis of the recovering small intestine suggested that
TIGAR might be important in both lowering apoptosis and allow-
ing cell growth and proliferation. Previous work has indicated
that TIGAR could contribute to these responses by limiting
oxidative damage and may promote the generation of metabolic
intermediates, such as nucleotides, that are necessary for tissue
expansion. To examine directly the defect that underlies the fail-
ure of TIGAR/ intestinal crypts to regenerate properly, we
turned to an in vitro intestinal crypt culture model (Sato et al.,
2009). Compared to cells derived fromWTmice, intestinal crypts
from TIGAR/mice were defective in their ability to proliferate in
this three-dimensional tissue culture model (Figures 4A and 4B).
TIGAR/ cells were less able to form crypt structures, and the
culture of these cells produced fewer new crypt outgrowths
over time (Figures 4A and 4B). Quantification of 100 individual
crypt structures of each genotype clearly showed the defect in
crypt formation in cultures from TIGAR/ cells (Figure 4C).
Direct staining of the crypt structures with Ki67 also showed
less proliferation in the TIGAR/ cultures, evenwhen comparing
crypt structures of similar size (Figure 4D), which is consistent
with the regeneration failure seen in vivo in these mice. This
defect could be rescued by the addition of N-acetyl L-cysteine
(NAC; to control ROS) and nucleosides (to compensate for any
lack of ribose phosphate production). Indeed, compared to the
WT crypts, essentially complete rescue was observed following
treatment with nucleosides or NAC alone (Figures 4A–4D). The
effect of NAC indicates an importance of antioxidant function
to the rescue, and interestingly we showed that treatment of cells
with nucleosides also resulted in an increase in the GSH/GSSG
ratio (Figure S4A), showing that nucleosides can also provide
antioxidant function. To explore the contribution of the nonoxi-468 Developmental Cell 25, 463–477, June 10, 2013 ª2013 Elsevier Idative branch of the PPP, we treated cultures with oxythiamine
(which inhibits transketolase in the nonoxidative PPP). Levels
of oxythiamine that did not affect the growth of WT crypts exac-
erbated the growth defect of TIGAR/ crypts (Figure S4B),
showing that loss of TIGAR makes cells more sensitive to inhibi-
tion of this branch of the PPP. Interestingly, oxythiamine also
somewhat impeded, but did not completely inhibit, the ability
of NAC to rescue the growth of TIGAR-null cells, again suggest-
ing that the main defect in these cells is in antioxidant function.
TIGAR Is Critical for Tumor Development in an Intestinal
Adenoma Model
Our results show that TIGAR plays an important role in allowing
growth and proliferation required for the repair of damaged intes-
tinal epithelium in adult mice. The modulation of metabolic path-
ways to allow anabolism and ROS limitation has been proposed
to play an important role in tumorigenesis. We were therefore
interested to determine whether TIGAR also contributes to the
abnormal proliferation of tumor cells in the intestine. To address
this question, we used a model in which the tumor suppressor
APC is deleted in LGR5+ intestinal stem cells, leading to the
development of intestinal adenoma (Barker et al., 2007, 2009).
Using a protocol involving multiple doses of tamoxifen to maxi-
mize the incidence of adenoma development, TIGAR-deficient
mice (knockout [KO]: TIGAR/ Lgr5-EGFP-IRES-creERT2/
APCfl/fl) showed a reduced burden of abnormally proliferating
adenoma in the small intestine compared tomicewithWT TIGAR
(WT: TIGAR+/+ Lgr5-EGFP-IRES-creERT2/APCfl/fl) (Figures 5A–
5D). Specifically, TIGAR-deficient mice showed a significant
reduction in total tumor burden and average tumor size
compared to WT mice (Figures 5B–5D). Staining of TIGAR in
WT tissues show a higher expression in the adenoma compared
with surrounding normal tissue (Figure 5A), which is consistent
with the role of TIGAR in supporting proliferation in tumor tissues.
Similarly, the TIGAR-deficient mice showed a reduction in size of
colon adenomas compared to WT mice (Figures 5E–5H).
Interestingly, when examining the colon, there were no signifi-
cant differences in the number of tumors in the colon (Figure 5F),
indicating that TIGAR may be more important for tumor growth
than for tumor initiation in this tissue. These results indicated
that the absence of TIGAR limited tumor development, and so
to determine the effect of TIGAR depletion on the survival of
mice, we turned to a protocol of a single tamoxifen induction,
which allows a slower onset of adenoma. As seen previously,
fewer and smaller tumors developed in the small intestine of
the TIGAR-deficient mice (Figures 5I–5L). In addition, there was
less proliferation (less Ki67 staining) and more ROS damage
(moreMDA staining) in TIGAR-null compared toWT animals (Fig-
ure 5I), indicating a contribution of TIGAR to proliferation and
ROS limitation that is similar to that seen following acute intesti-
nal damage. Staining of GFP as a marker of LGR5-positive stem
cells in these models (Barker et al., 2007, 2009) revealed that the
absence of TIGARdoes not deplete the tumors of stem cells (Fig-
ure S5). Overall, there appeared to be a slight decrease in the
number of crypts with positive GFP staining, although as with
the damage model this was difficult to interpret in view of the de-
fects in proliferation in TIGAR-null animals. Importantly, the
reduction in tumor burden correlated with an increased survival
of mice lacking TIGAR (Figure 5M).nc.
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Figure 4. Reduction of Proliferation in TIGAR-Deficient Intestinal Crypt Can Be Rescued by the Addition of ROS Scavengers and Nucleoside
(A) Crypt cultures from WT and TIGAR/ (KO) small intestines after the indicated treatment. The same crypts were followed on days 1, 3, and 5. Scale bar,
100 mm.
(B) Crypt cultures from WT and KO small intestines 5 days after the indicated treatment. Asterisks indicate growing buds from the crypt. Scale bar, 300 mm.
(C) Quantification of the number of buds (0 toR4) from the crypts from WT and KO small intestinal crypt cultures.
(D) Ki67 staining of the crypt cultures from WT and KO small intestine treated with the indicated drugs for 5 days. Scale bar, 100 mm.
See also Figure S4.
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Figure 5. TIGAR Deficiency Reduced the Tumor Burden in a Mouse Model of Intestinal Adenoma
(A) H&E staining (top), Ki67 staining (middle), and TIGAR staining (bottom) of the small intestines from TIGAR+/+ Lgr5-EGFP-IRES-creERT2/APCfl/fl (WT) mice and
TIGAR/ Lgr5-EGFP-IRES-creERT2/APCfl/fl (KO) mice after multiple rounds of tamoxifen induction.
(B) Number of tumors from WT and KO mice. *p < 0.05 compared to WT.
(C) Total tumor burden in the small intestine of WT and KO mice. *p < 0.05 compared to WT.
(legend continued on next page)
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for the Development of Intestinal Adenomas
The reduction of tumor progression in TIGAR-null mice was also
reflected in an in vitro tumor crypt culture model (Sato et al.,
2011). These cultures grow as large cystic organoids, which do
not show the differentiation or structural organization of similar
cultures derived from normal intestine (compare Figures 4A
and 6A). The tumor crypt cultures from TIGAR-deficient mice
showed a significant impairment of growth, as revealed by the
reduction of the crypt size (Figures 6A and 6B) and decreased
proliferation (Figures 6C and S6A) compared to those from WT
animals. To determine the underlying cause of the failure of
TIGAR-null tumor cells to grow, we examined the effect of
exogenous addition of either methyl-malate, which can provide
additional NADPH by a non-PPP mechanism via malic enzyme
(Frenkel, 1975; Schafer et al., 2009; Yang et al., 2010a), nucleo-
sides, or NAC to decrease ROS damage. Each of these treat-
ments partially rescued the defect in growth (Figures 6A and
6B) and proliferation (Figures 6C and S6A), while the addition
of NAC and malate also prevented the accumulation of ROS,
as measured by MDA staining (Figure 6D). Interestingly, treat-
ment of these tumor crypts with nucleosides also partially in-
hibited ROS damage (Figure 6D), consistent with our earlier
observation that nucleosides can help maintain GSH/GSSG ra-
tios (Figure S4A). However, in this system, complete rescue of
crypt size (Figures 6A and 6B) and proliferation (Figures 6C
and S6A) was only achieved when both malate and nucleosides
or NAC and nucleosides were provided. These results therefore
support an importance of TIGAR in generating both NADPH and
ribose phosphate to allow the growth of these highly proliferative
tumor cells. Although there are several mechanisms for NADPH
production, the PPP has been shown to be critical for redox bal-
ance in hypoxia (Anastasiou et al., 2011). Consistently, we found
that TIGAR-deficient crypts are more sensitive to hypoxia than
WT crypts (Figure 6E).
To confirm that the defects seen in these crypts were the result
of loss of TIGAR, we re-expressed human TIGAR in these cells
(Figure 6F). Interestingly, while WT TIGAR completely rescued
crypt growth, a partial rescuewas also seen following expression
of a catalytic inactive TIGAR construct (TIGAR-TM) (Bensaad
et al., 2006) (Figure 6F). These results suggest that a catalytically
independent role of TIGAR, such as a recently described ability
to enhance HK2 activity (Cheung et al., 2012), can contribute
to the maintenance of crypt growth.
Taken together, our results indicate that the defect in growth
shown by TIGAR-deficient tumor crypts reflects increased(D) Average size of tumor from WT and KO mice. *p < 0.05 compared to WT.
(E) H&E staining (top), Ki67 staining (middle), and TIGAR staining (bottom) of the c
bar, 200 mm.
(F) Number of tumors from the colon of WT and KO mice.
(G) Total colon tumor burden of WT and KO mice. *p < 0.05 compared to WT.
(H) Average colon tumor size of WT and KO mice. *p < 0.05 compared to WT.
(I) H&E staining (top), Ki67 staining (middle), and MDA staining (bottom) of the
TIGAR/ Lgr5-EGFP-IRES-creERT2/APCfl/fl (KO) after a single dosage of tamox
(J) Number of tumors from WT and KO animals. *p < 0.05 compared to WT.
(K) Total tumor burden in the small intestine of WT and KO animals. *p < 0.05 co
(L) Average size of tumor from WT and KO animals. *p < 0.05 compared to WT.
(M) Kaplan-Meier survival curves showing adenoma-free survival of WT (n = 5) a
See also Figure S5.
DevelROS and decreased nucleotide synthesis. Intriguingly, the
TIGAR/ crypts also showed an increased sensitivity to chemo-
therapeutic drugs compared to WT tumor crypts (Figure S6B).
The human TIGAR gene is p53 responsive, and cells contain-
ingWTp53 show elevation of TIGAR levels in response to various
forms of stress (Bensaad et al., 2006). The function of TIGAR
under these conditions contributes to cell survival and is likely
to allow for repair or adaptation of normal tissue to mild, tran-
sient, or nongenotoxic damage. However, our results in mice
suggest that TIGAR expression may also be advantageous to tu-
mor cells, and so we examined tumor cell lines to determine
whether the expression of TIGAR was strictly dependent on
the presence of WT p53. A survey of a number of p53/ or
mutant-p53-expressing tumor cell lines showed that TIGAR
expression was not dependent on the retention of WT p53 (Fig-
ure 7A). Therefore, the expression of TIGAR can become de-
coupled from p53 and there may be a selection for expression
of TIGAR during malignant progression.
To establishwhether TIGAR expression is also associatedwith
the development of human cancers, we examined a series of
colon tissue microarrays (TMAs) comparing normal, tumor, and
metastatic tissue from the same patient. Staining for TIGAR
expression by IHC showed an increase in TIGAR protein in
both the primary colon cancer and associated metastases
compared to normal tissue (Figures 7B and 7C). These results
are consistent with the suggestion that TIGAR expression can
help to support malignant development, potentially by allowing
rapid proliferation and expansion of the abnormal lesion.
DISCUSSION
We have generated TIGAR-deficient mice to investigate the
contribution of TIGAR to normal development and in rapidly
proliferating cells after acute tissue damage and during tumor
growth. TIGAR/ mice did not show a clear developmental
defect, suggesting either that TIGAR function is not required dur-
ing embryogenesis or that there is compensatory adaptation to
the constitutive lack of TIGAR during these stages of develop-
ment. However, we found a clear need for TIGAR in supporting
rapid proliferation of adult tissue, in particular the ability of the
adult intestinal epithelium to regenerate following damage. The
requirement for TIGAR under these conditions is also highlighted
by the increase in TIGAR expression seen in crypts during the re-
covery of proliferation in WT mice and by the corresponding in-
crease in oxidative damage in the TIGAR-deficient animals.
Whether there is a similar requirement for TIGAR in otherolon fromWT and KOmice after multiple dosage of tamoxifen induction. Scale
small intestines from TIGAR+/+ Lgr5-EGFP-IRES-creERT2/APCfl/fl (WT) and
ifen induction. Scale bar, 200 mm.
mpared to WT.
nd KO (n = 7) mice. Data are represented as mean ± SEM (n = at least 3).
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(A) Expression of TIGAR in various human cancer
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(B) Example of TIGAR staining in matched sam-
ples of human normal colon, colon adenocarci-
noma, and liver metastasis from the same patient.
(C) Quantification of the staining intensity in normal
human colon, primary adenocarcinoma (tumor),
and liver metastases.
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TIGAR Supports Intestinal Regenerationproliferative tissues remains to be determined, and a role for
TIGAR in recovery from partial hepatectomy or in mounting an
immune response will be extremely interesting to examine. Our
studies show that TIGAR plays an important role in tissue regen-
eration and that lack of TIGAR results in a failure to repair
damaged intestinal epithelium, with an associated increased
morbidity in a model of ulcerative colitis. In these systems, there-
fore, TIGAR expression is necessary to maintain normal healthy
tissues following stress or damage. The ability of TIGAR to
contribute to the growth and survival of cells in rapidly prolifer-Figure 6. Reduction of Proliferation in TIGAR-Deficient Tumor Crypt Can Be Rescued by the Addition of Malate and Nucleoside
(A) Tumor cystic organoid cultures from TIGAR+/+ Lgr5-EGFP-IRES-creERT2/APCfl/fl (WT) and TIGAR/ Lgr5-EGFP-IRES-creERT2/APCfl/fl (KO) small intestines
after the indicated treatment for 5 days. Bar = 100 mm.
(B) Quantification (average diameter of the organoids) of (A). *p < 0.05 compared to WT. ns, no significant difference.
(C) Quantification of the percentage of Ki67-positive cells in the tumor crypt cultures fromWT andKO animals treatedwith the indicated treatments for 5 days. *p <
0.05 compared to WT. ns, no significant difference.
(D) MDA staining of the tumor crypt cultures from WT and KO animals with the indicated treatments for 5 days. Scale bar, 100 mm.
(E) Size of TIGAR-deficient and control crypts following exposure to 1% oxygen (hypoxia) for 5 days. *p < 0.05 compared to WT.
(F) TIGAR-deficient and control crypts were electroporated with the indicated constructs and then cultured for 5 days. Crypts expressing comparable levels o
each protein, as visualized by FLAG staining, were measured for size. *p < 0.05 compared to KO with Ctr-FLAG. Data are represented as mean ± SEM (n = 3)
See also Figure S6.
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contribution of TIGAR to the development
or progression of malignancies. In a
mouse model of intestinal tumor induced
by deletion of APC in the intestinal stem
cells, TIGAR expression was increased
and we detected a reduction in tumor
development and enhanced survival in
TIGAR/ mice.
There has been much interest recently
in the revival of the suggestion that
altered metabolism can contribute to, as
well as respond to, oncogenic transfor-
mation. Several elegant studies have
illustrated the importance of metabolic
transformation in cancer development
(Freed-Pastor et al., 2012; Locasale
et al., 2011; Schafer et al., 2009; Ying
et al., 2012), although there is limited in-
formation about how these metabolic
changes may impact on tumorigenicity
in vivo. The regulation of glucose meta-
bolism by TIGAR may have several
important consequences; while thecontribution of TIGAR to antioxidant activity has been shown in
several cell systems (Bensaad et al., 2006; Li and Jogl, 2009;
Wanka et al., 2012), the potential promotion of the pentose phos-
phate pathway would also help to support anabolic pathways for
the production of lipids and nucleic acids, and so contribute
directly to cell growth (Tong et al., 2009). Although an inability
to properly regulate ROS may account for enhanced apoptosis
and so an indirect failure in cell proliferation, analysis of the re-
generating epithelium suggested that a transient increase in
apoptosis in the TIGAR/ mice (although this did not result inf
.
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recover proliferation. The importance of TIGAR in limiting ROS
was supported by the analysis of normal crypt cultures in vitro,
where the defect in TIGAR/ crypts was efficiently rescued by
treatment of the cells with antioxidant or nucleosides, with the
observation that nucleoside treatment also provided antioxidant
function. However, in the tumor crypt cultures, a full rescue of
growth defects in TIGAR-null cells required the addition of both
antioxidants (or NADPH generating capacity) and nucleosides,
suggesting that in these cells TIGAR is important in supporting
both antioxidant activity and nucleotide synthesis.
ROS has been suggested to both limit and promote tumor pro-
gression, reflecting the observation that different species of ROS
have different functions. While elevated ROS can both induce
potentially oncogenic mutations and function as a signaling
molecule to drive proliferation, excess mitochondrial ROS can
induce cell death and activation of pathways that block prolifer-
ation (Hamanaka and Chandel, 2010). These different ROS spe-
cies can be differentially controlled; for example, the glutathione
pool regulates oxidative stress while the peroxiredoxin pool reg-
ulates ROS signaling (Murphy, 2012). Therefore, it is possible
that TIGAR mainly lowers oxidative stress via managing the
glutathione level and has less of an impact on the regulation of
redox signaling (which would drive proliferation).
In humans, TIGAR is p53 inducible and has been suggested to
play a role under conditions of mild or transient stress to help
promote the repair and survival of damaged cells (Bensaad
et al., 2006; Li and Jogl, 2009; Wanka et al., 2012). These meta-
bolic functions of p53 can play a role in tumor suppression (Li
et al., 2012), and the activation of the pentose phosphate
pathway by ATM has been shown to enhance NADPH produc-
tion and increase nucleotide synthesis, so controlling ROS and
contributing to DNA repair. These responses were shown to be
important in allowing ATM to limit cancer development (Cosen-
tino et al., 2011). However, there is also a clear potential that
TIGAR activity, by limiting ROS and providing precursors for
nucleotide synthesis, could be advantageous to tumor cells (Tra-
chootham et al., 2006). Neoplastic cells generally produce more
ROS than normal cells (Szatrowski and Nathan, 1991); therefore,
they are more vulnerable to oxidative stress because they func-
tion with a higher basal level of ROS. On one hand, these higher
levels of ROS could promote tumor progression by stimulating
cell growth and proliferation (Hu et al., 2005), genetic instability
(Radisky et al., 2005), and anchorage-independent growth
(Weinberg et al., 2010). However, increased ROS also render tu-
mor cells more vulnerable to cell death and it is therefore essen-
tial for the tumor cells to dynamically regulate ROS level to avoid
prolonged oxidative damage. For example, oncogenes such as
K-Ras, B-Raf, and Myc all increase the activity of NRF2, a tran-
scriptional factor that increases ROS detoxification and tumori-
genesis at the early stages of tumor development (DeNicola
et al., 2011). Deletion of NRF2 in vivo reduces the ability of
K-Ras to induce proliferation and tumorigenesis (DeNicola
et al., 2011), supporting the importance of ROS limitation in
tumor outgrowth. One response to increased ROS is a decrease
in the activity of PKM2 through oxidation at cysteine in PKM2.
This diverts glycolytic intermediates into the PPP and, as we
describe for TIGAR, generates reducing potential for ROS detox-
ification. Importantly, this activity has been shown to be essential474 Developmental Cell 25, 463–477, June 10, 2013 ª2013 Elsevier Ifor tumor formation in a xenograft model (Anastasiou et al., 2011;
Tong et al., 2009).
Taken together, therefore, it would appear that TIGAR can
help to support tumorigenesis, both by limiting ROS and by
providing precursors for nucleotide synthesis. Both of these ac-
tivities can be provided by promotion of the PPP, although we
also provide evidence that the recently described catalytically in-
dependent function of TIGAR in ROS regulation under hypoxia
(Cheung et al., 2012) also contributes to its overall ability to sup-
port tumor cell growth.
It was therefore very interesting to determine that TIGAR was
highly expressed in many human colon cancers, consistent with
a contribution to the tumorigenic phenotype. Increased expres-
sion of TIGAR has recently also been described in other tumor
types, including glioblastomas and breast cancers (Wanka
et al., 2012; Won et al., 2012). Importantly, p53 is mutated in
the majority of colon cancers, suggesting that, as seen in the
cancer cell lines, selection for TIGAR overexpression is un-
coupled from the activity ofWTp53. This potential oncogenic ac-
tivity of a p53 target gene has also recently been described for
carnitine palmitoyltransferase 1c (Cpt1c), a p53-inducible gene
that contributes to fatty acid oxidation. Cpt1c is upregulated in
many cancer cell types and can protect against metabolic
stress and contribute to growth of the tumor (Zaugg et al.,
2011). Our observations indicate that the inappropriate or sus-
tained activation of proteins like TIGAR, uncoupled from the
dependence on p53,may help to support the growth and survival
of cancer cells.
Our studies show that the regulation ofmetabolismby TIGAR is
not required for normal tissue growth and development but
becomes important in supporting rapidproliferation in adult intes-
tinal epithelium. This specific requirement under conditions of tis-
sue regeneration has also been described for FAK (Ashton et al.,
2010), which is not needed in normal adult tissue but is required
for intestinal regeneration and tumorigenesis. Therefore, while
loss of TIGAR is deleterious to the recovery from intestinal dam-
age, lack of TIGAR becomes advantageous under conditions
where enhanced proliferation occurs in the context of tumor
development. These data clearly predict that inhibition of TIGAR
expression may carry some therapeutic advantage, although TI-
GAR inhibition would also be predicted to enhance the delete-
rious effects of genotoxic cancer therapies that damage normal
gut and other proliferating cells. Indeed, an increase in the TIGAR
level in the intestine may provide protection from acute intestinal
damage such as ulcerative colitis and intestinal radiosensitivity.
We are presently generating tumor models with our conditional
TIGAR allele to allow us to determine the effect of targeted dele-
tion of TIGAR in premalignant or malignant lesions.
EXPERIMENTAL PROCEDURES
Transgenic Mouse Models
Details of the creation of TIGAR/ and TIGARfl/flmice are provided in the Sup-
plemental Experimental Procedures. All animal work was carried out in line
with the Animals (Scientific Procedures) Act 1986 and the EU Directive 2010
and sanctioned by local ethical review process (University of Glasgow).
Creation of the Intestinal Adenoma Model with TIGAR–/–
To investigate the role of TIGAR in the development of intestinal adenoma due
to deletion of Apc in LGR5+ intestinal crypt cells (Barker et al., 2007, 2009),nc.
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generate TIGAR+/+ Lgr5-EGFP-IRES-creERT2/APCfl/fl (WT) and TIGAR/
Lgr5-EGFP-IRES-creERT2/APCfl/fl (KO). To induce recombination of APC in
LGR5-expressing cells, mice aged 6–8 weeks were injected intraperitoneally
with single dosage of tamoxifen (3 mg tamoxifen) or multiple dosages of
tamoxifen (3 mg of tamoxifen for 1 day followed by 2 mg of tamoxifen for
3 days). Mice were monitored until showing signs of intestinal illness, and tis-
sues were collected for histology, immunohistochemistry, and intestinal crypt
culture.
Cell Culture and Protein Analysis
BMK cells were cultured and used as previously described (Mathew et al.,
2008). Western blot analysis, transfection of the BMK cells with TIGAR con-
structs, measurement of Fru-2,6-BP, and GSH/GSSG were performed as pre-
viously described (Bensaad et al., 2006).
IR, Cisplatin Treatment, and DSS-Induced Colitis
Gamma IR-induced intestinal damage was performed as previously
described (Ashton et al., 2010). For cisplatin-induced intestinal damage,
cisplatin (10 mg/kg) was intraperitoneally injected into 8- to 10-week-old
mice. Saline was used as control. For DSS-induced colitis, mice received
2% or 3.5% of DSS in drinking water for 5 days. Then DSS was omitted
and mice received tap water for 2 days. Tap water was used as control. Intes-
tinal tissue was isolated and processed as described previously (Jamieson
et al., 2012).
Histology and Immunohistochemistry
Histology and immunohistochemistry was performed as described previously
(Sansom et al., 2004). Primary antibodies used were anti-Ki67 (Lab Vision),
anti-TIGAR (Millipore), anti-MDA (Abcam), anti-BrdU (Sigma), anti-Olfm4
(Abcam), anti-LGR5/GPR49 (Abcam), anti-GFP (Abcam), and anti-FLAG
(Sigma).
Small Intestinal Crypt Culture and Immunofluorescence
Small intestinal crypt culture and tumor crypt culture were performed as
described previously (Sato et al., 2009, 2011). Briefly, small intestine was
washed in cold PBS and villi were scraped using a glass coverslip. Then the
small intestine was cut into small pieces and the pieces were further washed
with cold PBS. The pieces were transferred into PBS with 2 mM EDTA and
incubated for 30 min, after which crypts were collected by pipetting mechan-
ically and supernatant enriched with crypts were collected. The crypts were
then pelleted by centrifugation (1,200 rpm, 5 min), suspended in ADF media
(advanced DMEM F12 [Invitrogen], 1% glutamine, 1% penicillin/streptomycin,
0.1% BSA, 10 mM HEPES), and passed through 70 mm cell strainer. The
fraction was then centrifuged at lower speed (600 rpm, 2 min) to avoid single
cells being spun down. The final pellet with crypt was resuspended with
growth factor reduced Matrigel (356231, BD) in ADF that contained
0.05 mg/ml EGF (Peprotech), 0.1 mg/ml NOGGIN (Peprotech), and 0.5 mg/ml
mR-Spondin (R&D Systems). For tumor crypts, adenomas were cut into small
pieces, washed, and then dissociated with trypsin for 30 min in 37C. After
several washes the cells were pelleted and were suspended with Matrigel in
ADF that contained EGF and NOGGIN. The cultures were passaged every
7–10 days. For the rescue experiments, 200 mM NAC (Sigma), 13 nucleoside
(Millipore), 2.5 mM methyl-malate (Sigma), and 10 mM oxythiamine (Sigma)
were added to the culture on the first day. Hypoxia was performed as
described previously (Cheung et al., 2012). For Amaxa nucleofection into can-
cer crypt organoids, 1 mg (per well) control, WT TIGAR, or catalytically TIGAR
mutant (TIGAR-TM) (Bensaad et al., 2006) constructs was transfected into
cancer crypt organoids using solution T and program X-001 (Lonza). The
rate of growth of the intestinal crypt was measured by the number of buds
present in at least 100 crypt structures as previously described (Mustata
et al., 2011). The rate of growth of the tumor crypt was measured by the
average size (diameter) of at least 150 crypts in each treatment from tumors
from three individual animals (WT and KO). For nucleofected cancer crypt
measurements, the average size (diameter) of at least 100 crypts that were
stained positive with FLAG was measured from cultures of three individual
animals (WT and KO).DevelImmunofluorescence of Crypt Cultures
Crypts were fixed with 2% paraformaldehyde (PFA) in PBS for 20 min at room
temperature and then permeabilized with 0.5% Triton X-100 in PBS for 10 min
at 4C. After three 10 min washes of 13 PBS-glycine (7.5 mg/ml) to quench
PFA, crypts were incubated with 10% BSA primary block in immunofluores-
cence wash (0.13 M NaCl, 13 mM Na2HPO4, 3.5 mM NaH2PO4, 0.2% Triton
X-100, 0.04% 3 Tween-20) for 1 hr, followed by incubation with secondary
block (10%BSA and 1:100 Fab immunoglobulin G [Jackson Immunoresearch]
in immunofluorescence wash) for 30 min. The primary antibody (prepared in
secondary block) was incubated overnight at 4C and washed three times in
immunofluorescence wash before incubation with the appropriate fluorescent
dye coupled secondary antibody (Alexa Fluor, Molecular Probes) for 1.5 hr.
DAPI (1 mg/ml) in 13 PBS was used to visualize nuclei.
Human TMA analysis
TMA of human cancer patients was obtained from AccuMax Array (A203(II)-
colon cancer tissues liver metastasis) and was stained with anti-human TIGAR
antibody (ProSci). The scoring of the TMAs was carried out by two indepen-
dent scorers.
Quantifications and Statistical Analysis
For crypt number counting in the small intestine, the intestinal length corre-
sponding to a minimum of 100 crypts per animal per treatment was measured
and was expressed as number of crypts per millimeter of intestinal length. For
crypt size measurements in the intestine, a minimum of 50 crypts were
measured for the height of the crypt. For cell death measurement in the crypts,
the number of cells exhibiting apoptotic morphology (Li et al., 1992; Merritt
et al., 1997) from at least 50 crypts per animal per treatment was scored and
was expressed as the average number per crypt. The number of Ki67-positive
cells was measured in at least 50 crypts per animal per treatment. The survival
data were analyzed by log-rank test using GraphPad Prism 5 software. The
data represent mean values ± SEM from at least three independent experi-
ments (n = 3) unless otherwise noted. All p values were obtained using two-
way ANOVA and Fisher’s post hoc tests.
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